Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695462 | 1.00 | ACLY (0.51) | ACLYALDH1A1SMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL3118833 | 0.87 | ACLY (0.48) | ACLYALDH1A1SMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL1110755 | 0.85 | VCAM1 (0.56) | ACLYALDH1A1SMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL8075375 | 0.84 | CA1 (0.51) | ACLYALDH1A1SMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL31704382 | 0.83 | ACLY (0.47) | ACLYALDH1A1SMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL31587402 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2L3MBTL1CYP1A2TSHR | |
| SCHEMBL6152074 | 0.82 | KDM4E (0.56) | ALDH1A1SMN1; SMN2L3MBTL1CYP1A2TSHR | |
| SCHEMBL669263 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2L3MBTL1CYP1A2TSHR | |
| SCHEMBL1495720 | 0.82 | ALDH1A1 (0.65) | ACLYALDH1A1SMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL11597913 | 0.81 | PTK2B (0.42) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| CN-117209469-A | Compounds as CLK inhibitors and uses thereof | 南京圣和药物研发有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3445756-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184623-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184623-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ACLY 2577/4885ALDH1A1 1898/4885SMN1; SMN2 2430/4885 |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ACLY 2577/4885ALDH1A1 1898/4885SMN1; SMN2 2430/4885 |
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ACLY 593/4885ALDH1A1 2613/4885SMN1; SMN2 3059/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | ACLY 2485/4885ALDH1A1 2609/4885SMN1; SMN2 2366/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | ACLY 1510/4885ALDH1A1 276/4885SMN1; SMN2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.